Impact of the CYP2D6 genotype on post‐operative intravenous oxycodone analgesia
- 8 January 2010
- journal article
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 54 (2), 232-240
- https://doi.org/10.1111/j.1399-6576.2009.02104.x
Abstract
Oxycodone is a semi-synthetic opioid with a mu-receptor agonist-mediated effect in several pain conditions, including post-operative pain. Oxycodone is metabolized to its active metabolite oxymorphone by O-demethylation via the polymorphic CYP2D6. The aim of this study was to investigate whether CYP2D6 poor metabolizers (PMs) yield the same analgesia post-operatively from intravenous oxycodone as extensive metabolizers (EMs). Two hundred and seventy patients undergoing primarily thyroid surgery or hysterectomy were included and followed for 24 h post-operatively. The CYP2D6 genotype was blinded until study procedures had been completed for all patients. All patients received intravenous oxycodone as pain treatment for 24 h post-operatively and morphine 5 mg was used as escape medication. A responder was characterized as a patient without the need for escape medication and a positive evaluation in a questionnaire 24 h post-operatively. Twenty-four patients were PM (8.9%) and 246 were EM (91.1%). One PM (4.17%, CI=0.1-21.1) was a non-responder and 42 EM (17.07%, CI=12.6-22.4) were non-responders. The non-responder rate did not differ between the two genotypes (P=0.14). There was no difference in the total consumption of oxycodone between the two genotypes (EM=14.7 mg, CI=13.0-16.4 and PM=13.0 mg, CI=8.9-17.0, P=0.42). The mean oxymorphone/oxycodone ratios were 0.0031 and 0.00081 in the EMs and PMs, respectively (P<0.0001). This study showed for the first time in patients that the oxymorphone formation depends on CYP2D6, but we found no difference in the post-operative analgesic effect of intravenous oxycodone between the two CYP2D6 genotypes.Keywords
This publication has 28 references indexed in Scilit:
- The Hypoalgesic Effect of Oxycodone in Human Experimental Pain Models in Relation to the CYP2D6 Oxidation PolymorphismBasic & Clinical Pharmacology & Toxicology, 2009
- Blood–Brain Barrier Transport Helps to Explain Discrepancies in In Vivo Potency between Oxycodone and MorphineAnesthesiology, 2008
- Pharmacological Characterization of Noroxymorphone as a New Opioid for Spinal AnalgesiaAnesthesia & Analgesia, 2008
- Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspectsPharmacology & Therapeutics, 2007
- Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: A randomized, double-blind, active- and placebo-controlled, parallel-group trialClinical Therapeutics, 2007
- Antinociception by Spinal and Systemic Oxycodone: Why Does the Route Make a Difference?Anesthesiology, 2006
- In Vivo Blood-Brain Barrier Transport of Oxycodone in the Rat: Indications for Active Influx and Implications for Pharmacokinetics/PharmacodynamicsDrug Metabolism and Disposition, 2006
- Efficacy and side effects of tramadol versus oxycodone for patient-controlled analgesia after maxillofacial surgeryEuropean Journal of Anaesthesiology, 1999
- Efficacy and side effects of tramadol versus oxycodone for patient-controlled analgesia after maxillofacial surgeryEuropean Journal of Anaesthesiology, 1999
- Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodoneJournal of Pain and Symptom Management, 1996